DENVER, Colorado — August 25, 2020 — OncBioMune d/b/a Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, announced today that Mick Ruxin, M.D., President and CEO of Theralink, will present at the LD 500 Virtual Conference on Tuesday, September 1, 2020.
Dr. Ruxin will present via live webcast at 10:40 a.m. ET in Track 3. To attend, please register here: https://www.webcaster4.com/Webcast/Page/2019/36068
The LD 500 Virtual Conference taking place from September 1-4, 2020 will feature prominent public companies, alongside interviews and keynotes with some of the most successful and influential business leaders in the small-cap world.
For more information about the LD 500, or to schedule a one-on-one meeting with Theralink’s management, please contact Theralink’s Investor Relations at Theralink@kcsa.com or David Scher at email@example.com.
About Theralink® Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling company, located in Golden, Colorado that uniquely specializes in patented, phosphoprotein and protein biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
Theralink Technologies, Inc.
KCSA Strategic Communications
Valter Pinto, Managing Director